Getinge

Strong Q2 26: Relief rally in full swing

17/07/26 -"Getinge delivered a solid Q2 26, beating consensus on both sales and adjusted EBITA. ACT returned to positive sales growth after a weak Q1; order trends were broadly encouraging across all divisions, ..."

PDF page sample
Pages
64
Language
English
Published on
17/07/26
Download
You may also be interested by these reports :
17/07/26
Getinge delivered a solid Q2 26, beating consensus on both sales and adjusted EBITA. ACT returned to positive sales growth after a weak Q1; order ...
16/07/26
China plans to implement VBP for capital equipment, which may pressure MedTech firms’ margins in the region. Additionally, the renewed US-Iran ...
10/07/26
Non Pharma Health stocks have long been suffering. The sector has lost 39% ytd, not  helped by EssilorLuxottica’s -35% correction. EL’s connected ...
23/06/26
There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO